Paclitaxel and curcumin co-loaded mixed micelles: Improving in vitro efficacy and reducing toxicity against Abraxane®

Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy

“…In order to encapsulate both drugs, RIF and CUR, the solvent diffusion method was used, as previously described [ 17 , 20 ]. Briefly, RIF (100 mg) and CUR (50 mg) were dissolved in 20 mL of acetone; the solution was sonicated for 5 min (Digital Ultrasonic Cleaner, PS-10A 50/60 Hz, Shenzhen, China, 25 °C) and then added drop by drop using a programmable syringe infusion pump (PC11UB, APEMA, Buenos Aires, Argentina) to the aqueous dispersion of Soluplus ® (10% w / v ) at room temperature under constant magnetic stirring (50 RPM, 4 h) to let the complete evaporation of the organic solvent, as well.…”

“…The CUR and RIF cumulative in vitro release from the nanomicelles with (0.7% w / v ) and without Gel(man) was studied by using dialysis method in SILF (pH 7.4) with the addition of ethanol (30% v / v ) [ 17 ] as external medium. Lyophilized micellar systems were redispersed in distilled water and further diluted with distilled water in order to achieve concentrations of 1 mg/mL for RIF and 0.5 mg/mL for CUR.…”

“…Curcumin (CUR) is a polyphenol compound obtained from Curcuma longa root currently used as an oral nutraceutical [ 16 ] and as an anti-inflammatory agent in Ayurveda medicine. Nevertheless, CUR exhibits low aqueous solubility [ 17 ], which hampers the development of liquid CUR dosage forms.…”

“…In a previous study, a respirable RIF-loaded nanocarrier based in Soluplus ® polymeric micelles demonstrated to have a significantly improved in vitro microbicidal efficacy in comparison with the RIF solution [ 20 ]. Soluplus ® is a graft copolymer of poly (vinyl caprolactam)-poly (vinyl acetate)-poly (ethylene glycol) (PEG) that showed good performance solubilizing poorly soluble drugs [ 15 , 16 , 17 ] and high micellar stability (due to its low CMC value). Hence, the present investigation was aimed at expanding the potential of this inhalable nanotechnological platform for an active drug targeting to the Mtb-infected macrophages.…”

Cancer nanotechnology: current status and perspectives

“…Nanoxel ® is a polymeric amphiphilic micelle formulation approved for clinical use in India in 2006 and is currently undergoing clinical trials for FDA approval (ClinicalTrials.gov Identifier: NCT04066335), and Apealea, approved for use in the European Union in 2018, utilizes poly-(lglutamic acid) conjugated to PTX. Unfortunately, peripheral neuropathy remains a clinical challenge despite improved formulations, further necessitating continued optimization [136].…”